Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

A humorous take on hair loss treatments, mentioning the use of minoxidil, finasteride, dutasteride, and unconventional methods. The conversation includes satire about extreme and fictional hair growth rituals.

OP is seeking recommendations for thickening tonics and decides to try Aveda thickening tonic after a suggestion. Another user recommends hair powder as an alternative.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

The conversation humorously discusses various hair loss treatments like RU58841, dutasteride, finasteride, PRP, Nizoral, broccoli stems, biotin, and head massages. It also touches on the idea of shaving one's head despite using these treatments.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The user is using a regimen of topical minoxidil and finasteride twice daily, derma rolling weekly, and biotin/DHT blocking shampoo and supplements to address hair loss. They are seeking advice on additional methods to improve results on the crown and temples.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

The conversation humorously suggests using immunosuppressants like ciclosporine and oral minoxidil for hair regrowth, with a satirical plan involving hair transplants from family members. It highlights the side effects and impracticality of such treatments, emphasizing the post's satirical nature.

The user is using 1mg oral finasteride daily, topical minoxidil on the hairline, a dermaroller weekly, Alpecin Caffeine shampoo daily, and ketoconazole shampoo weekly. The hairline appears to be improving after two months.

The user is experiencing hair loss and is considering increasing their dutasteride dosage or trying RU58841, but is concerned about the effectiveness and side effects. Other users suggest sticking with dutasteride 0.5 mg daily and adding oral minoxidil for better results.

The user is experiencing noticeable hair regrowth after 2 months using oral finasteride, topical minoxidil, weekly dermastamping, and ketoconazole shampoo. They report thicker hair, especially at the temples, and are surprised by the improvement.

The user is happy with their 2-month progress using a 3-in-1 oral tablet containing finasteride, minoxidil, and biotin, with minor side effects like slightly lower libido. They report no significant issues like breakouts and note that oral treatments are more effective than topical ones.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

The user shared a 2-month progress update using topical finasteride and minoxidil for hair loss. The conversation included comments on the user's appearance and potential side effects.

The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

GHK-Cu significantly improved hairline with baby hairs in 2 months, despite previous lack of results from oral dutasteride and minoxidil. OP suggests trying GHK-Cu due to noticeable hair regrowth.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.